| ²é¿´: 1789 | »Ø¸´: 55 | |||||||||
[½»Á÷]
¡¾2016-3-20¡¿¡¾´óÁ¬¡¿2016µÚ°Ë½ì¹ú¼Ê¿¹Ìå´ó»á
|
|||||||||
2016µÚ°Ë½ì¹ú¼Ê¿¹Ìå´ó»á ʱ¼ä£º2016Äê4ÔÂ25-28ÈÕ µØµã£ºÖйú ´óÁ¬ Ö÷Ì⣺¼ÓËÙÏÂÒ»´ú¿¹ÌåµÄÑз¢ »áÒéÍøÕ¾£ºhttps://www.bitcongress.com/ica2016/default.asp ¹ú¼Ê¿¹Ìå´ó»áÒѾ³É¹¦¾Ù°ì¹ýÆß½ì£¬ÒѳÉΪȫÇò¿¹ÌåÑо¿ÁìÓò×îרҵµÄ»áÒéÖ®Ò»¡£´ó»áÖÂÁ¦ÓÚΪȫÇòµÄ¿ÆÑ§¹¤×÷Õß¡¢Ñо¿»ú¹¹ºÍÏà¹ØÆóÒµ´î½¨Ò»¸ö×ÔÓɽ»Á÷µÄƽ̨£¬¼ÓÇ¿Õþ¸®×éÖ¯¡¢´óѧ¡¢Ñо¿»ú¹¹ºÍÆóÒµÖ®¼äµÄ¹µÍ¨ÓëÐ×÷£¬½øÒ»²½ÍƽøÖйúºÍÈ«ÊÀ½çÔÚ¿¹ÌåÑо¿ºÍÖÎÁÆÁìÓòµÄнøÕ¹¡£ ±¾½ì´ó»á½»Á÷ÄÚÈݰüÀ¨¿¹ÌåÑо¿Ð¼¼ÊõÐÂÇ÷ÊÆ£¬¿¹ÌåÒ©ÎïÑз¢¼°ÖÎÁÆ£¬¿¹ÌåÒ½ÁÆÕï¶Ï£¬¿¹Ì幤³Ì¼°Éú²ú¡¢ÉÌÎñºÏ×÷µÈ20¶à¸öרҵÐÔÂÛ̳£¬Ö¼ÔÚ´«µÝ¿¹ÌåÑо¿ÁìÓò¸÷¸ö·½ÃæµÄ×îÐÂ×ÊѶ£¬Õ¹Ê¾Í»ÆÆÐÔÑо¿³É¹û¡£´ó»á×éί»á½«ÑûÇë3λŵ±´¶û½±´óʦ³öϯ¿ªÄ»Ê½£¬²¢×öÖ÷Ìⱨ¸æ¡£»¹½«ÑûÇë¹ú¼ÊÖøÃûר¼ÒѧÕß¡¢¿¹ÌåÑз¢¹ú¼ÊÖØµãʵÑéÊÒ¡¢´óѧ¡¢Ñо¿ËùµÄÖ÷Òª¸ºÔðÈË¡¢¿¹ÌåÉú²úºÍÏúÊÛÆóÒµµÄ¸ß¹Ü×öרÌⱨ¸æ¡£ Ö÷ÌâÑݽ²ÈË Dr. Patrick Liu, Vice President, Teva Pharmaceuticals Ltd., USA Dr. Jose de Chastonay, Chief Marketing Officer, Bachem Holding AG, Switzerland Dr. Vadim T. Ivanov, Director and Professor, Russian Academy of Sciences, Russia Dr. Kelly T. McKee, Vice President, Quintiles Inc., USA Dr. Zhenping Zhu, Executive Vice President, Biologics President & CEO, Kadmon China, USA Ó¢ÎÄ·Ö×éÂÛ̳£¨Ñݽ²ÓïÑÔΪӢÎÄ£© Track 1 Global Antibody Market Trend, Business and Partnering Track 1-1 Promising Future and Challenge, Business and Cooperation in World Antibody Market Track 1-2 Industry Aspects, Policy, Regulation, IP Issues, Business and Trends in Antibody Market Track 1-3 IP Issues Track 2 New Technologies and Trends in Antibody Research Track 2-1: Novel Research in Immune System, Immunology and Immunogenicity of Antibodies Track 2-2: Immunoglobulin Diversity, Antibody Characterization Technologies and Structure Biology Track 2-3: Novel Antibody Library Technologies and Microarray Technologies, Nanotechnology, Biochips, Phage Display Technologies for Antibody Research Track 2-4: Enabled High Throughput/Content Technologies for Antibody Research - From Antibody Screening, Selection to Optimization Technologies Track 2-5: Antibody Humanization Technologies Track 2-6: Exploiting the Immune System and Immunotherapeutic Strategies ¨C from Vaccines to Cell-based and Protein Immunotherapy Track 2-7: Glycoengineered Antibodies, Agonist and Super-agonist Antibodies Track 2-8: Monovalent, Multivalent Antibodies, Fragments, Single-domain Antibody, and scFv Track 3 Advances in Antibody Drug and Therapy Track 3-1: Challenges and New Opportunities with Antibody and Protein Drugs Track 3-2: Innovative Antibody drugs in Clinical Trail and Development Track 3-3: Novel Antibody and Biologic Drug Targets Track 3-4: Antibody-drug Conjugate (ADC) Discovery and Development Track 3-5: Bispecific and Multispecific antibody discovery and development Track 3-6: Next Generation of Cancer Immune therapy and Anti-Cancer Antibody Track 3-7: Novel Therapeutic Antibodies for Infectious and Inflammatory Diseases Track 3-8: Novel Therapeutic Antibodies for Allergy, Asthma and Autoimmune Diseases Track 3-9: Antibodies for Pediatrics Diseases Track 3-10: Therapeutic Antibodies for Neurological Disease and other Neglected Diseases Track 4 Antibody Applications in Medical Diagnosis and other Non-Medical Field Track 4-1: Novel Antibodies in Medical Treatment and Diagnosis Track 4-2: Biomarker Development - Correlating with Antibody Therapy Track 4-3: Antibodies for Immunohistochemistry and Immunofluorescence Track 4-4: Antibody for Western Blot Analyses, ELISA and ELISPOT Techniques Track 4-5: Antibody Research in Agriculture, Aquaculture, Veterinary and Food Sciences Track 4-6: The ¡°standardisation¡± of Methods Using Antibodies for the Detection of Diseases and other Issues Track 5 Antibody Design, Engineering and Production Track 5-1: Analytical Strategies for Early Phase Protein Engineering and New Antibody Formats Track 5-2: Advances in Antibody Engineering and Design Strategies Track 5-3: Cell Line and Model Organisms Development for Antibodies Track 5-4: Novel Upstream Bioprocess Technologies in Antibody Production Track 5-5: Optimised Platform for Downstream Processing of Antibodies Track 5-6: Improved Purification and Modification Methods for Antibody Fragments Track 5-7: Novel Expressing Platform for Antibody Production Track 5-8: Biosimilars and Biobetters - Methods and Protocols Èç¹ûÄúÓÐÑݽ²»ò²Î»áµÄÒâÏò£¬ÇëÏÈÓë»áÎñ×éÁªÏµ¡£ ÁªÏµ·½Ê½ ÁªÏµÈË£ºÕÅŮʿ µç»°£º0411-84799609-842 ÓÊÏ䣺dannie@bit-ica.com µØÖ·£º´óÁ¬ÊиßÐÂÔ°Çø»ãÏÍÔ° 1 ºÅ 11 ²ã Óʱࣺ116025 |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸C9µÄ»¯Ñ§¹¤³Ì£¨085602£© 340·Ö£¬¸Ð¾õУÄÚµ÷¼ÁÎÞÍû£¬Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
312Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ9È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸ ½ÄÏ´óѧ 085602 »¯¹¤×¨Ë¶ 338·ÖÇóµ÷¼Á
ÒѾÓÐ14È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸ºÓ±±¹¤Òµ´óѧ²ÄÁϹ¤³Ì£¬³õÊÔ344Çóר˶µ÷¼Á
ÒѾÓÐ4È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
ÖØÇ칤ÉÌ´óѧ»·¾³Óë×ÊԴѧԺ/·ÏÓÍ×ÊÔ´»¯¼¼ÊõÓë×°±¸½ÌÓý²¿¹¤³ÌÑо¿ÖÐÐĽÓÊÕÑо¿Éúµ÷¼Á
+5/295
½Î÷¿Æ¼¼Ê¦·¶´óѧ ²ÄÁÏÓëÄÜÔ´ÕÐÊÕµ÷¼ÁÑо¿Éú
+1/92
Çൺ¿Æ¼¼´óѧµ÷¼ÁÕÐÉú
+1/55
¹ãÎ÷´óѧũѧԺ˶ʿÑо¿Éúµ÷¼Á£¨ÏÞ±¨¿¼×¨Òµ09¿ªÍ·£©4ÔÂ8ÈÕ¿ªÍ¨µ÷¼Áϵͳ
+2/46
ºÓ±±´óѧÎÞ»ú»¯Ñ§×¨ÒµÕÐÊÕµ÷¼ÁÉú
+1/40
´óÁ¬¹¤Òµ´óѧ·ÄÖ¯Óë²ÄÁϹ¤³ÌѧԺ³¬ÁÙ½çÁ÷Ìå¼¼Êõ¿ÎÌâ×é Ñо¿Éúµ÷¼Á
+2/38
ºÓÄϹ¤Òµ´óѧ»¯Ñ§»¯¹¤Ñ§Ôº 2026 Äê˶ʿµ÷¼ÁÕýÔÚ½øÐУ¡
+1/38
ÕÐÆ¸ ²©Ê¿½ÌʦÓбàÖÆ £¬²ÄÁϼӹ¤¹¤³Ì£¬½ðÊô²ÄÁÏ·½Ïò ÔÂн1.8WÆð£¬ µØµãÉÂÎ÷μÄÏ
+1/30
¡¾Ë¶Ê¿µ÷¼Á¡¿¡¾·Ö×Óҽѧ 10Ò½Àà ×îºó»ú»á¡¿2026ÄêÇൺ´óѧ˶ʿµ÷¼Á²¹ÕÐ
+1/21
Å·ÃËELIÏîĿ̫ºÕ×ÈС×éÕÐÊÕÌ«ºÕ×ȹâѧ²©Ê¿
+1/19
ÖØÇì´óѧ΢µç×ÓÓëͨÐŹ¤³ÌѧԺÕÅÀÚ½ÌÊÚ¿ÎÌâ×éÕÐÊÕ2026¼¶²©Ê¿Ñо¿Éú£¨2026Äê9ÔÂÈëѧ£©
+1/12
Ìì½ò¿Æ¼¼´óѧ¾¹ÜѧԺҦΰ½ÌÊÚÍŶӣºÖªÊ¶Éú̬Ñо¿ÖÐÐĽÓÊܹÜÀí¿ÆÑ§Ó빤³Ì2026µ÷¼ÁÉú
+1/9
Õã½Å©ÁÖ´óѧ-¹ð½ðɽ¿ÎÌâ×飨ֲÎïϸ°û±Ú-ÉúÎïÖÊÓëÉúÎïÄÜÔ´£©-2026Äê˶ʿÑо¿Éúµ÷¼Á
+1/8
¾ÍÒµºÃ-¹ã¶«Î¨Ò»Ê¯»¯ÔºÐ£¡ª¡ª×ÊÔ´Óë»·¾³×¨Ë¶ÕÐÉú
+1/8
³¤½Ê¦·¶Ñ§Ôº»¯Ñ§¹¤³Ì·½Ïò½ÓÊÕ´óÁ¿Ë¶Ê¿Ñо¿Éúµ÷¼Á¿¼Éú
+1/8
½ËÕ´óѧ»¯Ñ§»¯¹¤Ñ§Ôº2026Äê˶ʿÑо¿ÉúÕÐÉúµ÷¼Á¹«¸æ
+1/5
³¤½Ê¦·¶Ñ§Ôº ²ÄÁϹ¤³Ì ÕÐÊÕµ÷¼ÁѧÉú
+1/5
³¤½Ê¦·¶Ñ§Ôº»¯Ñ§»¯¹¤Ñ§Ôº»¯Ñ§¹¤³Ì·½Ïò½ÓÊÕ´óÁ¿µ÷¼Á¿¼Éú
+1/4
ºÓ±±´óѧÕÐÊÕµÈÀë×ÓÌåÎïÀíµ÷¼ÁÉú
+1/3
¹þ¶û±õ¹¤³Ì´óѧ¶¯Á¦Ñ§ÔºÕÔ½¨»ÔÍŶÓÕÐÊÕ2026²©Ê¿Ñо¿Éú
+1/2
13Â¥2016-01-22 11:31:33
24Â¥2016-01-22 12:10:01
¼òµ¥»Ø¸´
hxlhxl-12Â¥
2016-01-22 11:17
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ºÃ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
ÌìÑÄsx3Â¥
2016-01-22 11:20
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ԭö4¥
2016-01-22 11:22
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
2016-01-22 11:22
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
mike20006Â¥
2016-01-22 11:24
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
tangfeng20167Â¥
2016-01-22 11:25
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
SilenceGoo8Â¥
2016-01-22 11:26
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
a
ZRZR9Â¥
2016-01-22 11:26
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ºÃ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
syhorchid10Â¥
2016-01-22 11:28
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ymz-111Â¥
2016-01-22 11:28
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Â仨½£Óê12Â¥
2016-01-22 11:29
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ÖÐɽÑò14Â¥
2016-01-22 11:38
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
bixuejian15Â¥
2016-01-22 11:39
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
1
tzynew16Â¥
2016-01-22 11:44
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
billie11317Â¥
2016-01-22 11:46
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë


jerry_dlut18Â¥
2016-01-22 11:59
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
ľÃ×ÔÂ…š19Â¥
2016-01-22 12:00
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
nono200920Â¥
2016-01-22 12:05
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
¡¤
matianvc21Â¥
2016-01-22 12:07
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
yukaiv22Â¥
2016-01-22 12:08
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

Ö§³Ö
gaomanb23Â¥
2016-01-22 12:08
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

liuzhuit25Â¥
2016-01-22 12:13
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
maoanj26Â¥
2016-01-22 12:13
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
tbs2027Â¥
2016-01-22 12:14
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
zhifang88928Â¥
2016-01-22 12:17
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ŷ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
meifangy29Â¥
2016-01-22 12:19
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

yongxiny30Â¥
2016-01-22 12:20
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

½£Ö®ºá31Â¥
2016-01-22 12:20
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
¾Í ·¢×ÔСľ³æAndroid¿Í»§¶Ë
chenyangl32Â¥
2016-01-22 12:21
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

chaoluib33Â¥
2016-01-22 12:21
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

jiunaj34Â¥
2016-01-22 12:21
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

shenmiaow35Â¥
2016-01-22 12:22
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

tudiank36Â¥
2016-01-22 12:22
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

nieliangl37Â¥
2016-01-22 12:25
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

Ö§³Ö
²éÀíÍÃ×Ó38Â¥
2016-01-22 12:25
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
Ŷ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
ÄÉÃײÄÁÏ75339Â¥
2016-01-22 12:26
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

yuhuaw40Â¥
2016-01-22 12:26
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
fengzuoy41Â¥
2016-01-22 12:27
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

liangluoj42Â¥
2016-01-22 12:28
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

ºúæÃ1743Â¥
2016-01-22 12:29
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
£¡ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
sunnaiv44Â¥
2016-01-22 12:32
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

fangfenj45Â¥
2016-01-22 12:32
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
fengyingm46Â¥
2016-01-22 12:32
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë

Ö§³Ö
stirith47Â¥
2016-01-22 12:38
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
С³æ199248Â¥
2016-01-22 12:39
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
rongtianv49Â¥
2016-01-22 12:40
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£
chenguw50Â¥
2016-01-22 12:41
»Ø¸´
dz×Ï΢À¶(½ð±Ò+1): лл²ÎÓë
×£¸£





»Ø¸´´ËÂ¥